Has Chrisann Kyi, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,232 in general payments to Chrisann Kyi, MD across 2 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Chrisann Kyi, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Chrisann Kyi, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Chrisann Kyi, MD

Medical Oncology · New York, NYNPI 1043509912

Payments from drug & device makers

What this record shows

This record is dominated by education: $2,139 of the $2,232 with a category attached, or 95.8%. Every reported general payment came from a single manufacturer, Eli Lilly. That places this record below the midpoint for medical oncology clinicians in NY, where the typical reported total is $4,912.

$2,232in general payments, 2019–2025

Across 2 payments — averaging $1116.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Eli Lilly$2K

$2,147,988in research payments, 2019–2025

Across 102 payments — averaging $21,059 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$1.4M
E.r. Squibb & Sons, L.L.C.$393K
AstraZeneca$374K
Incyte Corporation$26K

What the payments were for

Food & beverage$934%
Education$2,13996%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Eli Lilly	2	$2,232

How this compares

$2,232 in reported general payments places this provider in the 40th percentile of 498 medical oncology providers in New York.

See all medical oncology providers in New York →

Medicare billing

Part B allowed, 2024

$67,922

Medicare patients

143

Services billed

589

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
LynparzaOlaparib	25	$283,591
ZejulaNiraparib Tosylate	11	$191,112
XareltoRivaroxaban	23	$16,069
Dexamethasone	35	$862
Gabapentin	56	$840
Olanzapine	33	$756
Duloxetine Hcl	24	$647
Letrozole	35	$593
Ondansetron Hcl	83	$432
Prochlorperazine Maleate	17	$269
Levothyroxine Sodium	16	$229
Losartan Potassium	31	$183
Oxycodone Hcl	12	$154
Lorazepam	24	$143
Pantoprazole Sodium	13	$143

Paid to pharmacies, not to this prescriber.

Other medical oncology in New York

Craig ThompsonNew York$4.8M
Andrew SeidmanNew York$1.3M
Joshua RichterNew York$971K
Edward GelmannNew York$944K
Ghassan Abou-AlfaNew York$825K
Miguel PeralesNew York$769K
Komal JhaveriNew York$642K
Joshua BrodyNew York$492K
Aiwu HeNew York$445K
Raajit RampalNew York$418K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →